GWPH - GW Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
114.50
-3.50 (-2.97%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close118.00
Open119.00
Bid0.00 x 800
Ask0.00 x 800
Day's Range112.14 - 120.30
52 Week Range90.14 - 196.00
Volume834,453
Avg. Volume591,409
Market Cap3.417B
Beta (3Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-3.29
Earnings DateNov 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est226.46
Trade prices are not sourced from all markets
  • Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes
    Zacks

    Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes

    Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.

  • Penumbra Enrolls First Patient for Study on Coronary Vessels
    Zacks

    Penumbra Enrolls First Patient for Study on Coronary Vessels

    Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.

  • QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits
    Zacks

    QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits

    QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

  • How to Invest in Emerging Industries Like Marijuana
    Zacks

    How to Invest in Emerging Industries Like Marijuana

    Investors are still crazy about the pot stocks despite this year's roller coaster ride.

  • GlobeNewswire

    GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30, 2019 and Host Conference Call on November 5, 2019

    CARLSBAD, Calif., Oct. 09, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and.

  • Benzinga

    Jim Cramer Gives His Opinion On Disney, Carnival Corp And More

    On CNBC's "Mad Money Lightning Round," Jim Cramer said he doesn't understand how New Relic Inc (NYSE: NEWR ) could have such a degradation. Leidos Holdings Inc (NYSE: LDOS ) is a winner and it ...

  • Does GW Pharmaceuticals plc's (NASDAQ:GWPH) CEO Salary Reflect Performance?
    Simply Wall St.

    Does GW Pharmaceuticals plc's (NASDAQ:GWPH) CEO Salary Reflect Performance?

    Justin Gover became the CEO of GW Pharmaceuticals plc (NASDAQ:GWPH) in 1999. This report will, first, examine the CEO...

  • GW Pharmaceuticals: Target Price and Valuation Update
    Market Realist

    GW Pharmaceuticals: Target Price and Valuation Update

    Thirteen analysts are covering GW Pharmaceuticals in October. Nine covered the stock in October 2018. The consensus target price for the stock is $226.85.

  • Is GW Pharmaceuticals (GWPH) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is GW Pharmaceuticals (GWPH) Stock Outpacing Its Medical Peers This Year?

    Is (GWPH) Outperforming Other Medical Stocks This Year?

  • Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock?
    Zacks

    Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock?

    Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.

  • The Zacks Analyst Blog Highlights: Innovative Industrial, GW Pharmaceuticals and Canopy
    Zacks

    The Zacks Analyst Blog Highlights: Innovative Industrial, GW Pharmaceuticals and Canopy

    The Zacks Analyst Blog Highlights: Innovative Industrial, GW Pharmaceuticals and Canopy

  • Barrons.com

    GW Pharma Stock Has Plunged as Analyst Raises Questions Over Safety of Cannabis-Based Epilepsy Drug

    Epidiolex was launched last November as the first cannabis medicine approved in the U.S. Shares of GW Pharmaceuticals have slumped, even though sales of the drug are soaring. The stock could go even lower.

  • Here's Why You Should Add Thermo Fisher to Your Portfolio
    Zacks

    Here's Why You Should Add Thermo Fisher to Your Portfolio

    Investors continue to be optimistic about Thermo Fisher's (TMO) performance.

  • Pot Stocks to Win as America Roots for Decriminalizing Drugs
    Zacks

    Pot Stocks to Win as America Roots for Decriminalizing Drugs

    Marijuana stocks have reversed recent losses as report finds that Americans favor decriminalizing all drugs. Thus, investing in cannabis stocks for the moment won't be a bad proposition.

  • Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System
    Zacks

    Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System

    Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.

  • Cannabis Countdown: Top 10 Marijuana Stock News Stories Of The Week
    Benzinga

    Cannabis Countdown: Top 10 Marijuana Stock News Stories Of The Week

    Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the  Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10  marijuana stock news  stories for ...

  • Medtronic's All Business Lines Grow Despite Cost Concerns
    Zacks

    Medtronic's All Business Lines Grow Despite Cost Concerns

    Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.

  • Boston Scientific (BSX) Upbeat on Results of EVOLVE Study
    Zacks

    Boston Scientific (BSX) Upbeat on Results of EVOLVE Study

    Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.

  • NuVasive Announces Innovations in Robotics Spine Surgery Line
    Zacks

    NuVasive Announces Innovations in Robotics Spine Surgery Line

    NuVasive (NUVA) aims to speed up the adoption of less invasive spine surgery through robotics.

  • MarketWatch

    Oppenheimer lowers GW Pharma price target, tweaks revenue forecasts for Epidiolex

    Oppenheimer cut its stock price target for GW Pharmaceuticals PLC on Friday, after a poll of 25 prescribers of the company's Epidiolex, the only cannabis-based drug to win U.S. Food and Drug Administration approval as a treatment for severe forms of epilepsy. Analysts Esther Rajavelu and Benjamin Fages lowered their 2019 to 2020 revenue forecasts based on new patient acquisition rates and dosing regiments, increased their mid-term revenue forecast -- defined as for 2021 to 2024 -- based on a higher proportion of maintenance patients versus new ones, and lowered their long-term revenue forecasts -- for the 2025 to 2030 period -- based on gradually rising attrition rates and a declining net price. "These changes lower our PT to $233 from $239, and we maintain our outperform rating as we believe Epidiolex US uptake continues to progress well, and we await management comments on EU pricing/commercial strategy," the analysts wrote in a note to clients. The third-quarter forecast assumes 3,400 new patients for the drug, raising the total to 15,400 from 12,000 in the second quarter. Shares were up 0.4% in premarket trade, and have gained 29% in 2019, while the ETFMG Alternative Harvest ETF has fallen 12% and the S&P 500 has gained 19%.

  • GW Pharmaceuticals Stock Is Dashing Towards a Brighter Future
    TipRanks

    GW Pharmaceuticals Stock Is Dashing Towards a Brighter Future

    GW Pharmaceuticals (GWPH) announced on Monday that it had received approval to sell its epilepsy drug in the world's largest market, as measured by GDP.The European Commission gave its approval for GW Pharmaceuticals to sell EPIDYOLEX in the EU. This is the same drug used to treat the same conditions associated with epilepsy in the U.S., where it's branded as EPIDIOLEX; they're both the same drug.While GWPH stock is down a whopping 35% since May's high, Wall Street analysts still see a significant turnaround. Out of 8 analysts polled by TipRanks in the last 3 months, all 8 are bullish on the stock. With a healthy return potential of 77%, the stock’s consensus target price stands at $224.38. (See GWPH's price targets and analyst ratings on TipRanks)Great growth potentialEven though the EU only accounts for less than seven percent of the global population, its GDP is the largest in the world. The EU also has an overall favorable outlook toward cannabis-based products, and also in some cases, cover them with insurance, such as in Germany. They also tend to command higher prices as well. It remains to be seen whether or not the price of EPIDYOLEX will find higher price points than its U.S. counterpart, but even if it doesn't, this is a huge win for GW Pharmaceuticals.One interesting aside here is how this will play out with Brexit approaching. That's important because the UK hasn't been as enthusiastic over EPIDYOLEX as the rest of the EU has been, and once it leaves the economic bloc, it could result in a period of time before it is allowed to be sold in the UK.The National Health Service (NHS) admits that EPIDYOLEX reduces the frequency of seizures, but has questions about the long-term effect of the treatment, which at this time it considers an unknown. Other concerns were pointed out in regard to "the way the company modeled the effect on patients living longer or having a better quality of life."But when NICE Director Meindert Boysen said it wants to work with GW to deal with economic modeling issues, it suggests the real issue concerns the NHS getting a larger discount in order to cut costs to the agency.With or without the UK, the EU still represents a formidable market that is going to generate a lot more sales for GW in the future.What EPIDYOLEX/EPIDIOLEX doesEPIDYOLEX/EPIDIOLEX are used as a treatment for seizures associated with Lennox‑Gastaut syndrome or Dravet syndrome. EPIDYOLEX is the first cannabidiol oral solution to be approved of by the European Medicines Agency.It is derived from CBD, which means it doesn't have any significant amount of THC in it, which is what makes users high.EPIDYOLEX will be used in conjunction with clobazam as part of the treatment. Patients have to be two years of age or older in order to be treated.Approval for the treatment came after results from "four randomised, controlled Phase 3 trials." It included over 714 patients that had either LGS or Dravet syndrome.The two conditions have been found to be significantly resistant to existing drug treatments.Chairman, Dravet Syndrome European Federation, Isabella Brambilla, said this:“The approval of cannabidiol oral solution is an important milestone for patients and families whose lives are significantly impacted by these rare, complex and life-long forms of epilepsy. We are very happy that patients will now have access to a much-needed, new treatment option, and one routed through a rigorous clinical trials program and licensed by the EMA.”There has been high demand for an alternative to existing treatment options that have a chance of better controlling seizures and providing a better quality of life for all affected by the two conditions.With the mortality rates being high and the huge burden on families from the need to monitor loved ones because of the risk of injuries and falls from the condition, it is a long-term treatment that will benefit GW and the patients using EPIDYOLEX.Company's pipelineThe approval in the EU is important because it provides a strong revenue stream for GW while it develops its potentially formidable pipeline. It's already working on the development of Sativex.Other treatments it's working on include symptoms associated with autism, epilepsy, glioblastoma and schizophrenia. Those are now in Phase 1, 2 and 3 trial stages. When considering the number of people within the autism spectrum alone, it represents an enormous market. Estimates are that 1 percent of the global population has autism spectrum disorder. In America, about 3.5 million citizens live with it. Costs in the U.S. for adult services are from $175-196 billion, with costs for children in a range of $61-66 billion.There is growing demand for alternatives to potentially addictive drugs that have in many cases have severe side effects. GW has an opportunity to meet a portion of that demand, even though I expect the traditional medical community to try to crush it to protect their interests.Nonetheless, I see CBD-based treatments as being unstoppable, and at best they will be slowed down, and in some cases, as with EPIDIOLEX, rapidly approved of because of superior results and weaker side effects.With a pipeline like it has and the approval by the EU for EPIDYOLEX, GW has a visible and strong growth trajectory ahead of it.In the second quarter, Epidiolex generated net sales of $68.4 million for the company, up 204 percent sequentially. With total sales of $72 million in the quarter, it represented sales that were over 2,000 percent higher year-over-year.Expectations are the company will also be given approval to treat Tuberous Sclerosis Complex some time in 2020. This disorder brings about noncancerous tumors that spread throughout the body. A side effect of TSC is epilepsy. GW Pharma estimates there are up to 80,000 Americans that have the condition, as possibly 2 million around the world.ConclusionAccording to investment bank Evercore ISI, peak sales in the U.S. for Epidiolex will reach close to $1.3 billion. Assuming at least a similar level of sales in the EU, it shows the potential growth GW has in the near term, not taking into account its pipeline.Assuming it gets the go ahead to treat Tuberous Sclerosis Complex, it will provide revenue streams as it works on getting other treatments in its pipeline approved.In the first half of 2019, the company had an operating loss of $80.7 million, but that was down 46 percent year-over-year. That should continue to improve going forward, as GW scales into the EU.With a visible revenue stream from EPIDIOLEX and sales in the EU from EPIDYOLEX coming in the near future, combined with probable sales coming from Tuberous Sclerosis Complex, along with a pipeline with a lot of potential, it's apparent GW Pharmaceuticals is a company with a lot of growth left in it.With a Smart Score of ‘9’, this is a company with multiple positive datapoints, including a Strong Buy analyst consensus and positive activity from bloggers and hedge funds. Get the GWPH stock research report.

  • Align Gains on Innovation Despite Poor Case Shipment in China
    Zacks

    Align Gains on Innovation Despite Poor Case Shipment in China

    Align Technology (ALGN) succeeds in consecutively delivering a solid spurt in Invisalign Technology volumes across the company's entire clientele.

  • Natera (NTRA) Scales 52-Week High: What's Driving the Stock?
    Zacks

    Natera (NTRA) Scales 52-Week High: What's Driving the Stock?

    Natera (NTRA) is likely to maintain the current high on a number of favorable factors.

  • Benzinga

    'Renewed Sense Of Hope': GW Pharma CEO Talks Epilepsy Drug Approval In Europe

    Epidiolex is the only CBD-approved treatment for childhood-onset epilepsy, and its products will be introduced to 28 countries across Europe in the coming years, Gover said during a "Mad Money" interview Tuesday.

  • UK Approves Another Medicinal Cannabis Product
    Market Realist

    UK Approves Another Medicinal Cannabis Product

    GW Pharmaceuticals has announced the European Commission's approval of EPIDYOLEX. This will mark its entry into all European countries, including the UK.